Skip to main content
Book cover

Testosterone pp 365–388Cite as

Long-term experience with testosterone replacement through scrotal skin

  • Chapter

Abstract

Testosterone is the primary endogenous androgenic hormone. Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for the maintenance of secondary sex characteristics. The goals of treating male hypogonadism are the development or restoration of secondary sex characteristics, sexual function, and normal metabolic processes, and prevention of chronic bone loss (Bhasin 1992; Bhasin and Bremner 1997; Ghusn and Cunningham 1991). This chapter will summarize the clinical experience with Testoderm, a transdermal delivery system for testosterone, and the evidence of meeting treatment goals while providing a therapy for chronic use that is generally safe and does not produce untoward side effects with chronic treatment.

Keywords

  • Bone Mineral Density
  • Benign Prostatic Hyperplasia
  • Prostate Volume
  • Testosterone Concentration
  • Testosterone Replacement

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-642-72185-4_13
  • Chapter length: 24 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   84.99
Price excludes VAT (USA)
  • ISBN: 978-3-642-72185-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   109.99
Price excludes VAT (USA)
Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahmed SR, Boucher AE, Manni A, Santen RJ, Bartholomew M, Demers LM (1988) Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 66: 546–551

    CrossRef  PubMed  CAS  Google Scholar 

  • Bals-Pratsch M, Knuth UA, Yoon Y-D, Nieschlag E (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet 2: 943–946

    CrossRef  PubMed  CAS  Google Scholar 

  • Bals-Pratsch M, Langer K, Place VA, Nieschlag E (1988) Substitution therapy of hypogonad-al men with transdermal testosterone over one year. Acta Endocrinol 118: 7–13

    PubMed  CAS  Google Scholar 

  • Behre HM, Bohmeyer J, Nieschlag E (1994) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 40: 341–349

    CrossRef  CAS  Google Scholar 

  • Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82: 2386–2390

    CrossRef  PubMed  CAS  Google Scholar 

  • Bhasin S (1992) Clinical review 34: Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 74: 1221–1225

    CrossRef  PubMed  CAS  Google Scholar 

  • Bhasin S, Bremner WJ (1997) Emerging issues in androgen replacement therapy. J Clin Endocrinol Metabol, 82: 3–7

    CrossRef  CAS  Google Scholar 

  • Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R (1997) Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metabol 82: 407–413

    CrossRef  CAS  Google Scholar 

  • Bridges NA, Hindmarsh PC, Pringle PJ, Matthews DR, Brook CGD (1993) The relationship between endogenous testosterone and gonadotrophin secretion. Clin Endocrinol 38:373– 378

    Google Scholar 

  • Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson MA, Pandian MR, Galmarini M, Bhasin S (1993) Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 59: 1118–1123

    PubMed  CAS  Google Scholar 

  • Carey PO, Howards SS, Vance ML (1988) Transdermal testosterone treatment of hypogonadal men. J Urol 140: 76–79

    PubMed  CAS  Google Scholar 

  • Cofrancesco Jr J, Dobs AS (1996) Transdermal testosterone delivery systems. Endocrinologist 6: 207–213

    CrossRef  Google Scholar 

  • Cofrancesco Jr J, Walen III J J, Dobs AS (1997) Testosterone replacement treatment options for HIV-infected men. J Acquired Immune Deficiency Syndrome and Human Retrovirology 16: 254–265

    CrossRef  CAS  Google Scholar 

  • Cunningham GR, Cordero E, Thomby JI (1989) Testosterone replacement with transdermal therapeutic systems; physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 261: 2525–2530

    CrossRef  PubMed  CAS  Google Scholar 

  • de Lignieres B (1995) Effect of high dihydrotestosterone plasma levels on prostate of aged men. Abstract 2nd International Androgen Workshop. February 17–20 1995. Long Beach CA

    Google Scholar 

  • Dobs A et al. (1998) submitted for publication

    Google Scholar 

  • Findlay JC, Place VA, Snyder PJ (1987) Transdermal delivery of testosterone. J Clin Endocrinol Metab 64: 266–268

    CrossRef  PubMed  CAS  Google Scholar 

  • Findlay JC, Place V, Snyder PJ (1989) Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clinical Endocrinol Metab 68: 369–373

    CrossRef  CAS  Google Scholar 

  • Ghusn HF, Cunningham GR (1991) Evaluation and treatment of androgen deficiency in males. Endocrinologist 399–408

    Google Scholar 

  • Gooren LJG (1986) Long-term safety of the oral androgen testosterone undecanoate. Inter J Androl 9: 21–26

    CrossRef  CAS  Google Scholar 

  • Grinspoon S, Corcoran C, Lee K, et al. (1996) Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 81: 4051–4058

    CrossRef  PubMed  CAS  Google Scholar 

  • Ito, T, Horton R (1971) The source of plasma dihydrotestosterone in man. J Clin Invest 50: 1621–1627

    CrossRef  PubMed  CAS  Google Scholar 

  • Jackson J, Waxman J, Spiekerman A (1989) Prostatic complications of testosterone replace-ment therapy. Arch Intern Med 149: 2365–2366

    CrossRef  PubMed  CAS  Google Scholar 

  • Jordan WP Jr (1997) Allergy and topical irritation associated with transdermal testosterone administration; a comparison of scrotal and nonscrotal transdermal systems. Amer J Contact Dermatitis 8: 108–113

    CrossRef  Google Scholar 

  • Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM (1991) Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 146: 1566–1570

    PubMed  CAS  Google Scholar 

  • Kuttenn F, Mowszowicz I, Mauvais-Jarvis P (1980) Androgen metabolism in human skin. In: Mauvais-Jarvis P, Vickers CFH, Wepierre J (eds) Percutaneous absorption of steroids. Academic Press, London

    Google Scholar 

  • Lesser MA (1946) Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endo 6: 549–557

    CrossRef  CAS  Google Scholar 

  • Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA (1997) Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 49: 191–196

    CrossRef  PubMed  CAS  Google Scholar 

  • Nieschlag E, Cuppers HJ, Wieglmann W, Wickings FJ (1976) Bioavailability and LH suppres-sing effects of different testosterone preparations in normal and hypogonadal men. Horm Res 7: 138–145

    CrossRef  PubMed  CAS  Google Scholar 

  • Orwoll ES, Klein RF (1995) Osteoporosis in men. Endocr Rev 16: 87–116

    PubMed  CAS  Google Scholar 

  • Place VA, Atkinson LE, Prather DA, Trunnell N, Yates FE (1990) Transdermal testosterone replacement through genital skin. In: Nieschlag E and Behre H (eds). Testosterone: action, deficiency, substitution. Springer-Verlag, Heidelberg Berlin, pp 165–181

    Google Scholar 

  • Snyder PJ, Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 51: 1335–1339

    CrossRef  PubMed  CAS  Google Scholar 

  • Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75: 1092–1098

    CrossRef  PubMed  CAS  Google Scholar 

  • Vierhapper H, Nowotny P, Waldhausl W (1997) Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab 82: 1492–1496

    CrossRef  PubMed  CAS  Google Scholar 

  • von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM (1997) Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-l and lipoprotein (a). J Clin Endocrinol Metab 82: 3367–3372

    CrossRef  Google Scholar 

  • Wilson JD (1996) Androgens In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) Goodman and Gilman’s The Pharmaceutical Basis of Therapeutics, Ninth Edition. McGraw-Hill, New York, pp 1441–1457

    Google Scholar 

  • Yu Z, Gupta SK, Hwang SS, Cook DM, Duckett MJ, Atkinson LE (1997 a) Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application.J Clin Pharmacol 37: 1129–1138

    PubMed  CAS  Google Scholar 

  • Yu Z, Gupta SK, Hwang SS, Kipnes MS, Mooradian AD, Snyder PJ, Atkinson LE (1997 b) Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J Clin Pharmacol 37: 1139–1145

    PubMed  CAS  Google Scholar 

  • Zgliczynski S, Ossowski M, Slowinska-Szrednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M, Sadowski Z (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121: 35–43

    CrossRef  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Linda E. Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Lin Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter J. Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Reproductive Medicine, University of Münster, Domagkstrasse 11, D-48129, Münster, Germany

    Prof. Dr. med. Eberhard Nieschlag & Priv.-Doz. Dr. med. Hermann M. Behre & 

Rights and permissions

Reprints and Permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Atkinson, L.E., Chang, YL., Snyder, P.J. (1998). Long-term experience with testosterone replacement through scrotal skin. In: Nieschlag, E., Behre, H.M. (eds) Testosterone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72185-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72185-4_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72187-8

  • Online ISBN: 978-3-642-72185-4

  • eBook Packages: Springer Book Archive